Following its move in October to eliminate comparative efficacy studies for biosimilars in development, last week the FDA made further strides to streamline the biosimilar approval process in the United States.
On Tuesday, the Centers for Medicare & Medicaid Services (CMS) announced the next 15 drugs that will be subject to government price negotiations.
Last week, under a rarely used procedure known as a discharge motion, the House of Representatives passed a three-year extension of the enhanced Affordable Care Act (ACA) healthcare tax credit, which expired on December 31.
Yesterday, the Food and Drug Administration (FDA) announced long-overdue reforms to the biosimilar approval process that will boost biosimilar development and competition in the United States.
The One Big Beautiful Bill (OBBB), signed into law on July 4, 2025, prevented a large, scheduled tax hike from hitting American households.
The individual provisions of the Tax Cuts and Jobs Act (TCJA) are set to expire at the end of 2025. The Republican-controlled Congress intends to extend these tax cuts but some Republican lawmakers are demanding changes.
